Campbell & CO Investment Adviser LLC Makes New Investment in Stoke Therapeutics, Inc. $STOK

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 30,418 shares of the company’s stock, valued at approximately $715,000.

Several other hedge funds also recently modified their holdings of the company. Marshall Wace LLP lifted its holdings in shares of Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after buying an additional 168,771 shares during the period. Goldman Sachs Group Inc. raised its position in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after acquiring an additional 293,072 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Stoke Therapeutics by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock valued at $11,044,000 after acquiring an additional 70,935 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Stoke Therapeutics by 67.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock valued at $21,156,000 after purchasing an additional 362,299 shares in the last quarter. Finally, MPM Bioimpact LLC grew its stake in shares of Stoke Therapeutics by 13.8% in the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company’s stock worth $8,963,000 after purchasing an additional 95,710 shares during the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 3,978 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total value of $128,409.84. Following the completion of the sale, the general counsel directly owned 11,831 shares in the company, valued at approximately $381,904.68. The trade was a 25.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,662 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.34, for a total value of $114,767.08. Following the transaction, the insider owned 19,798 shares in the company, valued at approximately $620,469.32. This trade represents a 15.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 104,705 shares of company stock worth $3,070,910. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Trading Up 0.1%

Shares of NASDAQ STOK opened at $28.72 on Wednesday. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $38.69. The business has a 50-day moving average price of $30.96 and a two-hundred day moving average price of $24.70. The firm has a market capitalization of $1.64 billion, a PE ratio of 42.87 and a beta of 1.10.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on STOK. Canaccord Genuity Group increased their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Needham & Company LLC upped their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wedbush increased their price target on Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. Finally, JPMorgan Chase & Co. lifted their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.10.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.